Iterum Therapeutics to Present Data at IDWeek 2024
Iterum Therapeutics (Nasdaq: ITRM) announced its participation in IDWeek 2024, presenting three posters at the conference in Los Angeles from October 16-19, 2024. The presentations focus on the company's oral antibiotic sulopenem and its applications in treating uncomplicated urinary tract infections (uUTI) and inhalational anthrax.
The posters include results from the REASSURE trial on oral sulopenem/probenecid for uUTI, an analysis of asymptomatic bacteriuria in uUTI patients from the same trial, and the efficacy of sulopenem in a rabbit model of inhalational anthrax. All presentations will be given by Dr. Steven I. Aronin on October 18, with specific times and locations provided.
Iterum Therapeutics will make these posters available on their website's 'Publications: Posters & Presentations' page after the conference concludes.
Iterum Therapeutics (Nasdaq: ITRM) ha annunciato la propria partecipazione a IDWeek 2024, presentando tre poster durante la conferenza a Los Angeles dal 16 al 19 ottobre 2024. Le presentazioni si concentrano sull'antibiotico orale sulopenem e sulle sue applicazioni nel trattamento delle infezioni urinarie non complicate (uUTI) e dell'antrace inalato.
I poster includono i risultati del trial REASSURE sull'utilizzo di sulopenem/probenecid per le uUTI, un'analisi della batteriuria asintomatica nei pazienti con uUTI partecipanti allo stesso trial, e l'efficacia del sulopenem in un modello di conigli di antrace inalato. Tutte le presentazioni saranno tenute dal Dott. Steven I. Aronin il 18 ottobre, con orari e luoghi specifici forniti.
Iterum Therapeutics renderà disponibili questi poster sulla pagina 'Publications: Posters & Presentations' del loro sito web dopo la conclusione della conferenza.
Iterum Therapeutics (Nasdaq: ITRM) anunció su participación en IDWeek 2024, presentando tres carteles en la conferencia en Los Ángeles del 16 al 19 de octubre de 2024. Las presentaciones se centran en el antibiótico oral sulopenem y sus aplicaciones en el tratamiento de infecciones urinarias no complicadas (uUTI) y ántrax por inhalación.
Los carteles incluyen resultados del ensayo REASSURE sobre sulopenem/probenecid para uUTI, un análisis de la bacteriuria asintomática en pacientes con uUTI del mismo ensayo, y la eficacia de sulopenem en un modelo de conejo de ántrax por inhalación. Todas las presentaciones serán realizadas por el Dr. Steven I. Aronin el 18 de octubre, con horarios y ubicaciones específicos proporcionados.
Iterum Therapeutics pondrá estos carteles a disposición en la página de 'Publicaciones: Carteles y Presentaciones' de su sitio web después de la conclusión de la conferencia.
Iterum Therapeutics (Nasdaq: ITRM)는 2024년 10월 16일부터 19일까지 로스앤젤레스에서 열리는 IDWeek 2024에 참가하여 세 가지 포스터를 발표한다고 발표했습니다. 발표는 회사의 경구용 항생제 술로페넴 및 비구성 요로 감염 (uUTI)과 흡입 탄저병 치료에 대한 응용에 초점을 맞추고 있습니다.
포스터에는 uUTI에 대한 경구 술로페넴/프로베네시드에 대한 REASSURE 시험의 결과, 같은 시험에서 uUTI 환자의 무증상 박테리아뇨 분석, 그리고 흡입 탄저병의 토끼 모델에서 술로페넴의 효능이 포함됩니다. 모든 발표는 Dr. Steven I. Aronin이 10월 18일에 할 예정이며, 구체적인 시간과 장소가 제공됩니다.
Iterum Therapeutics는 회의가 끝난 후 자사의 웹사이트 '출판물: 포스터 및 발표' 페이지에 이 포스터를 공개할 예정입니다.
Iterum Therapeutics (Nasdaq: ITRM) a annoncé sa participation à IDWeek 2024, présentant trois affiches lors de la conférence à Los Angeles du 16 au 19 octobre 2024. Les présentations se concentrent sur l'antibiotique oral sulopenem et ses applications dans le traitement des infections urinaires non compliquées (uUTI) et de l'anthrax inhalé.
Les affiches incluent des résultats de l'
Iterum Therapeutics mettra ces affiches à disposition sur la page 'Publications : Affiches et Présentations' de son site Web après la fin de la conférence.
Iterum Therapeutics (Nasdaq: ITRM) hat seine Teilnahme an der IDWeek 2024 angekündigt und wird vom 16. bis 19. Oktober 2024 in Los Angeles drei Poster auf der Konferenz präsentieren. Die Präsentationen konzentrieren sich auf das orale Antibiotikum Sulopenem und dessen Anwendung zur Behandlung von unkomplizierten Harnwegsinfektionen (uUTI) und inhalativem Milzbrand.
Die Poster beinhalten Ergebnisse der REASSURE-Studie über orale Sulopenem/Probenecid bei uUTI, eine Analyse der symptomatischen Bakteriurie bei uUTI-Patienten aus der gleichen Studie und die Wirksamkeit von Sulopenem in einem Kaninchenmodell für inhalativen Milzbrand. Alle Präsentationen werden von Dr. Steven I. Aronin am 18. Oktober gehalten, mit spezifischen Zeiten und Orten, die bereitgestellt werden.
Iterum Therapeutics wird diese Poster nach Abschluss der Konferenz auf der Seite 'Publikationen: Poster & Präsentationen' ihrer Website verfügbar machen.
- None.
- None.
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America’s IDWeek 2024 conference taking place in Los Angeles, CA from October 16-19, 2024.
Data to be presented at IDWeek 2024 include:
Presentation Title: Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial
Poster #: 1107
Presenter: Steven I. Aronin, MD
Time/Location: Friday, October 18, 12:15 p.m. - 1:30 p.m.
Presentation Title: Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial
Poster #: 1574
Presenter: Steven I. Aronin, MD
Time/Location: Rapid Fire Poster Presentation, Friday October 18, 12:35 p.m. - 12:40 p.m., Halls JK – Arena 4.
Presentation Title: Sulopenem is Efficacious in a Rabbit Model of Inhalational Anthrax
Poster #: 1106
Presenter: Steven I. Aronin, MD
Time/Location: Friday, October 18, 12:15 p.m. - 1:30 p.m.
These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has submitted an NDA for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women, which has been accepted for review by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
What data will Iterum Therapeutics (ITRM) present at IDWeek 2024?
When and where will Iterum Therapeutics (ITRM) present at IDWeek 2024?
Who will present Iterum Therapeutics' (ITRM) data at IDWeek 2024?
What is the REASSURE trial mentioned in Iterum Therapeutics' (ITRM) IDWeek 2024 presentations?
How can I access Iterum Therapeutics' (ITRM) IDWeek 2024 posters after the conference?
